Skip to content
Enough Ventures

We turn deep science into companies that serve people.

We work with researchers and founders to assess the science, find a route to market and build the partnerships a company needs.

Actinium-225

89 protons, 136 neutrons. Targeted alpha therapy.

Current work

Companies and projects we lead, support or helped build. Each is shown at the stage it has reached.

  • Nuclear innovation

    Radion Robotics

    What it is
    A venture built on research from Brazil's national nuclear research institutes.
    What it builds
    Radiopharmaceutical production technology for nuclear medicine.
    Our role
    We lead commercialization, through our managing partner.
    Stage
    Patent family in preparation (2 of 5 submitted)
  • Deep tech

    Xelios

    What it is
    A lab automation company in formation.
    What it builds
    Lab automation for advanced cell workflows, for research use only.
    Our role
    We lead company formation, from the first workflow to a pilot.
    Stage
    Company formation in progress
  • Industrial software

    Limis

    What it is
    An industrial software company.
    What it builds
    Software that digitizes manufacturing operations.
    Our role
    We support commercial strategy, with Arkus Innovation Studios.
    Stage
    In commercial use
  • AI and innovation

    Arkus Innovation Studios

    What it is
    An AI-Native Innovation Consulting Studio.
    What it builds
    The AI Readiness Diagnostic.
    Our role
    We focus on the intersection of AI Adoption, Edge Computing, and Innovation Space Design.
    Stage
    Operating
  • Medical device

    Pedtrak

    What it is
    A medical device company founded by nurses.
    What it builds
    A device that finds and monitors pulses in the arms and legs.
    Our role
    We support commercialization, through our managing partner.
    Stage
    Founder began military service in 2026
  • Healthcare wearables

    LifeLensAR

    What it is
    A healthcare wearables company.
    What it builds
    A wearable augmented reality system for healthcare monitoring.
    Our role
    We co-founded and led the company, through our managing partner.
    Stage
    Acquired in 2025

Stages as of November 2026.

More on our current work

The people behind it

CNEN
Chandler J. Lewis is an Innovation and Commercialization Fellow at Brazil's National Nuclear Energy Commission.
NASA
He was formerly at NASA and co-founded LifeLensAR, a healthcare wearables company acquired in 2025.
100+
Businesses Krisztina Kapuvári helped launch across Francophone West Africa as co-founder of theSPACE NGO.
4
Regions where the partners work: North America, Latin America, Europe and Africa.

Meet the partners

Where we focus

Deep tech, nuclear innovation and social impact. Hard science, chosen for who it serves.

Deep tech

Companies built on hard science and engineering, where the advantage is technical, protectable and slow to copy.

AI for scientific discovery, robotics and automation for labs, healthcare and industry, advanced materials and biomaterials, diagnostics and computational biology.

Nuclear innovation

Peaceful nuclear science moving out of research institutes and into hospitals, industry and supply chains.

Nuclear medicine and radiopharmaceuticals, isotope supply, automation and remote handling for radiological work, radiation measurement and safety.

Social impact

Work whose benefit reaches people beyond those who fund it, in ways that can be shown.

Wider access to care, safer work in high-risk settings, more sustainable materials and processes, founders and regions that venture capital overlooks.

The question we ask of everything we take on

Who is better off if this works, and can that be shown?

Impact is not a side project or a reporting exercise for us. If we cannot say who is better off and how we would know, we pass.

More on our focus

More than 3,300 isotopes are known. Only a few serve people every day.

Technetium-99m and lutetium-177 made it from the laboratory to the clinic. Helping more research make that trip is our work.

Each block is one isotope. Its height is the number of decays it takes to become stable.

  • Stable, found in nature
  • Neutron-rich
  • Proton-rich
  • Heavy, sheds alpha particles

Who we work with

Most of our work starts with a researcher or a founder who has the science and needs help taking it to market.

You have validated science and no clear route to market. We help you choose a license, a spinout or a partnership, then build it with you.

  • A plain read on commercial potential before more is spent on protection
  • Help choosing between a license, a spinout and a partnership
  • A commercialization plan your technology transfer team can work with
  • Introductions to operators and investors once the case is ready

What we do for researchers

  • Researchers and institutions

    You have validated science and no clear route to market. We help you choose a license, a spinout or a partnership, then build it with you.

    What we do for researchers
  • Founders

    You are building on hard science and need commercial proof, partners and capital. We work beside you from formation through early financing.

    What we do for founders
  • Investors

    Family offices and funds that want a technically grounded view of deep-tech and nuclear work. Conversations are private.

    How VentureIP works
  • Companies, agencies and foundations

    Bring a research, deployment or market-access question that someone in our network can help you test.

    How the network works

From research result to a route to market

The usual order of the work. The pieces often overlap, and not every route ends in a new company.

  1. Step 1

    Assess

    You leave withA technical and IP readout you can act on.

  2. Step 2

    Position

    You leave withA chosen route to market and the reasons for it.

  3. Step 3

    Build

    You leave withA company, a license or a partnership with a plan behind it.

  4. Step 4

    Prepare for funding

    You leave withIntroductions made when the case is ready, not before.

How each step worksStep 1 runs through VentureIP

The network, drawn as a molecule. Each kind of relationship holds three kinds of partner. VentureIP and Arkus Raise sit between the stages they connect.

Research, commercialization and investment partners

Taking science to market takes more than one kind of expertise. We bring in each at the stage where it helps.

Research and development
Research institutes, universities, technical experts.
Commercialization
Operators, corporate partners, technology transfer teams.
Investment
Partner funds, family offices, strategic investors.

How the network works

The partners

Three partners who work directly on what the firm takes on.

  • Chandler J. Lewis

    Managing Partner

    Seattle and São Paulo

    Thesis, commercialization strategy, nuclear and deep-tech partnerships

  • Krisztina Kapuvári

    General Partner and Co-Founder

    United Kingdom and Europe

    Founder support, ecosystem partnerships, social impact

  • Mike Lee

    General Partner and Co-Founder

Meet the partners

Tell us what you need next.

Start with a short note on what you are working on. It goes straight to a partner.